10th International Symposium on the Clinical Use of Cellular Products

First Program

Cellular Therapy 2019

March 22 and 23, 2019, Erlangen, Germany
First Program

10th International Symposium on the Clinical Use of Cellular Products

Cellular Therapy 2019

March 22 and 23, 2019

Department of Internal Medicine 5 – Hematology/Oncology
University of Erlangen-Nuremberg

Department of Dermatology
University of Erlangen-Nuremberg

Department of Internal Medicine 3 – Hematology/Oncology
University of Regensburg

Department of Internal Medicine 2 – Hematology/Oncology
University of Würzburg
Dear Colleagues.

On behalf of the organizing committee we would like to invite you to join us for the 10th International Cellular Therapy Symposium, to be held in Erlangen, Germany, from March 22 to 23, 2019. The Cellular Therapy Symposium will be co-organized by the Universities of Erlangen-Nuremberg (A. Mackensen; G. Schuler), Regensburg (W. Herr), and Würzburg (H. Einsele).

Recent advances in protein engineering and molecular biology have increased the feasibility of cellular therapies such as genetically engineered T cells (CARs & TCRs) to treat malignant diseases.

Over the past years the meeting has evolved to a widely respected event, attracting experts from all over the world to discuss recent topics of the field in a pleasant environment. The upcoming meeting 2019 will focus on preclinical and clinical aspects of CAR T-cell therapy, TCR-engineered T-cell therapy, immunological checkpoints, and the tumor immune microenvironment.

We are sure that your participation will contribute making the meeting exciting and successful. You are cordially invited to join us at this symposium in the beautiful city of Erlangen.

Yours sincerely

Prof. Andreas Mackensen
Organizer: Andreas Mackensen, Erlangen  
Gerold Schuler, Erlangen  
Wolfgang Herr, Regensburg  
Herrmann Einsele, Würzburg  

Scientific Committee: Andreas Mackensen, Erlangen  
Hinrich Abken, Regensburg  
Michael Hudecek, Würzburg  
Claudia Rössig, Münster  
Matthias Theobald, Mainz  
Wolfgang Uckert, Berlin  
Simone Thomas, Regensburg  
Anita Kremer, Erlangen  
Dimitrios Mougiakakos, Erlangen  
Philipp Beckhove, Regensburg  
Robert Zeiser, Freiburg  
Andreas Beilhack, Würzburg  
Matthias Edinger, Regensburg  
Regina Jitschin, Erlangen  
Marina Kreutz, Regensburg  
Alexander Steinkasserer, Erlangen  
Heiko Bruns, Erlangen  

Congress Secretary: Prof. Dr. Dimitrios Mougiakakos  
Department of Internal Medicine 5 – Hematology and Oncology  
Ulmenweg 18  
D-91054 Erlangen, Germany  
Phone: +49-9131-85 35954  
Fax: +49-9131-85 35958  
E-mail: info@cellular-therapy.de  

Location: Hörsaalgebäude  
Universitätsklinikum Erlangen  
Ulmenweg 18  
D-91054 Erlangen, Germany
Friday March 22, 2019

Session I

CAR T-Cells - Preclinical

09.00 h – 11.15 h

- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
  Renier Brentjens (New York)

- Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for AML
  Saar Gill (Philadelphia)

- Mouse models for CRS & neurotoxicity due to CAR T cells
  Attilio Bondanza (Basel)

2 – 3 short presentations
(selected from submitted abstracts)
Friday March 22, 2019

Session II

CAR T-Cells – Clinical

13.30 h – 15.30 h

- Next generation CAR T cells for lymphoma/myeloma
  
  *Carl June (Philadelphia)*

- HER2neu CAR T cells in sarcoma patients
  
  *Nabil Ahmed (Houston)*

- GD2-targeting CAR T cell therapy
  
  *Karin Straathof (London)*

2 – 3 short presentations

*(selected from submitted abstracts)*
Friday March 22, 2019

Session III

TCR-engineered T-Cell Therapy

16.00 h – 18.15 h

■ TCR-engineered T-cell immunotherapy of cancer
  *Thomas Blankenstein (Berlin)*

■ TCR-engineered T-cell therapy
  *Stan Riddell (Seattle)*

■ NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease
  *Chiara Bonini (Milano)*

2 – 3 short presentations
*(selected from submitted abstracts)*
Saturday March 23, 2019

Session IV

Immunological Checkpoints

09.00 h – 11.15 h

- The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
  *Laurence Zitvogel (Villejuif)*

- Determinants of immunological response to immune checkpoint blockade in human cancer
  *Daniela Thommen (Amsterdam)*

- PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
  *Jürgen Ruland (Munich)*

2 – 3 short presentations
*(selected from submitted abstracts)*
Saturday March 23, 2019

Session V

Modulation of the Tumor-Immune Microenvironment

13.00 h – 15.00 h

- T-cell based immunotherapy and the tumor microenvironment
  *Hans Schreiber (Chicago)*

- Understanding the tumor immune microenvironment for effective therapy
  *Dmitry Gabrilovich (Philadelphia)*

- Analysis of immune-tumor cell interactions using patient-specific organoids
  *Niels Halama (Heidelberg)*

2 – 3 short presentations
*(selected from submitted abstracts)*
Session VI
Immunometabolism
14.15 h – 16.15 h

- Overcoming metabolic checkpoints to anti-tumor immunity
  Greg M. Delgoffe (Pittsburgh)

- Metabolic reprogramming enabling rapid CD8 T-cell recall responses
  Christoph Hess (Basel)

- New dimension of evasion mechanism for tumors – immunometabolic editing
  Ping-Chih Ho (Lausanne)

2 – 3 short presentations
(selected from submitted abstracts)
General Information

Scientific Sessions:

- CAR T-Cells Preclinical-Clinical
- TCR-engineered T-Cell Therapy
- Immunological Checkpoints
- Immune Effector Cells (T-Cells, NK-Cells)
- Antigen Presenting Cells
- Suppressor Cells (Treg-Cells, MDSCs, MSCs)
- Modulation of the Tumor-Immune Microenvironment

Submission of Abstracts: Deadline: January 31, 2019

Abstract submission will be available on the Cellular Therapy website beginning November 1, 2018. To submit an abstract for consideration and review, please go to http://www.cellular-therapy.de and click on Abstract Submission icon. Submission instructions and guidelines will appear.

All abstracts selected for oral or poster presentation will be printed in an abstract book, available to the participants.
Registration:

Participants are given the opportunity to register for the symposium online. Please adhere to the instructions given on the symposium website

http://www.cellular-therapy.de

Registration fee:

<table>
<thead>
<tr>
<th></th>
<th>Pre-registration (before Feb. 21, 2019)</th>
<th>On site-registration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full Registration:</strong></td>
<td>275 €</td>
<td>350 €</td>
</tr>
<tr>
<td>Students:</td>
<td>150 €</td>
<td>225 €</td>
</tr>
<tr>
<td>Employee of Uni ER or R or WÜ:</td>
<td>75 €</td>
<td>100 €</td>
</tr>
</tbody>
</table>

The registration fee covers conference volume, coffee breaks, lunch and social event

Please register early as attendance will be limited to 350 participants!!!
**Hotel Reservation:**

For further information please contact:

Erlanger Tourismus und Marketing Verein e.V.
Carree am Rathausplatz
Rathausplatz 3
91052 Erlangen
Phone: ++49 (0)9131 8951-11
Fax: ++49 (0)9131 8951-51
E-mail: tourist@etm-er.de
E-mail: city-management@etm-er.de

**Poster Presentation:**

Posters (100 cm wide and 120 cm high)
Deadline for abstracts: January 31, 2019
Congress Secretary: Prof. Dr. Dimitrios Mougikakos
Department of Internal Medicine 5 – Hematology and Oncology
Ulmenweg 18
D-91054 Erlangen, Germany
Phone: +49-9131-85 35954
Fax: +49-9131-85 35958
E-mail: info@cellular-therapy.de